Since the expression of immune checkpoints has become a biomarker of immunotherapy for HCC patients, we also analyzed the correlation between patient risk score and key immune checkpoints (CTLA4, PDL1, LAG3, TIGIT, IDO1, TDO2). This evidence concerns the gene TIGIT and hepatocellular carcinoma.